Acute Liver Failure: Biomarkers Evaluated by the Acute Liver Failure Study Group.
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
19
12
2022
accepted:
20
01
2023
medline:
1
5
2023
pubmed:
31
1
2023
entrez:
30
1
2023
Statut:
epublish
Résumé
There has been a growing interest in identifying prognostic biomarkers that alone or with available prognostic models (King's College Criteria, KCC; MELD and ALFSG Prognostic Index) would improve prognosis in acute liver failure (ALF) patients being assessed for liver transplantation. The Acute Liver Failure Study Group (ALFSG) has evaluated 15 potential prognostic biomarkers: serum AFP; apoptosis-associated proteins; serum actin-free Gc-globulin; serum glycodeoxycholic acid; sRAGE/RAGE ligands; plasma osteopontin; circulating MBL, M-, L-, H-ficolin and CL-1; plasma galectin-9; serum FABP1; serum Lct2; miRNAs; factor V; thrombocytopenia, and sCD163. The ALFSG also has reported on 4 susceptibility biomarkers: keratins 8 and 18 (K8/K18) gene variants; polymorphisms of genes encoding putative APAP-metabolizing enzymes ( UGT1A1 , UGT 1A0 , UGT 2B15 , SULT1A1 , CYP2E1 , and CYP3A5 ) as well as CD44 and BHMT1 ; single nucleotide polymorphisms (SNPs) of genes associated with human behavior, rs2282018 in the arginine vasopressin ( AVP ) gene and rs11174811 in the AVP receptor 1A gene. Finally, rs2277680 of the CSCL16 gene in HBV-ALF patients. In conclusion, we have reviewed the prognostic and susceptibility biomarkers studied by the ALFSG. We suggest that a better approach to predicting the clinical outcome of an ALF patient will require a combination of biomarkers of pathogenic processes such as cell death, hepatic regeneration, and degree of inflammation that could be incorporated into prognostic models such as KCC, MELD or ALFSG PI.
Identifiants
pubmed: 36716224
doi: 10.14309/ctg.0000000000000565
pii: 01720094-202304000-00007
pmc: PMC10132708
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00565Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK058369
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK058369
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137(12):947–54.
Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013;369(26):2525–34.
Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: Recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007;35(11):2498–508.
Bernal W, Hyyrylainen A, Gera A, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013;59(1):74–80.
Karvellas CJ, Safinia N, Auzinger G, et al. Medical and psychiatric outcomes for patients transplanted for acetaminophen-induced acute liver failure: A case-control study. Liver Int 2010;30(6):826–33.
Pezzia C, Sanders C, Welch S, et al.; Acute Liver Failure Study Group. Psychosocial and behavioral factors in acetaminophen-related acute liver failure and liver injury. J Psychosom Res 2017;101:51–7.
Stravitz RT, Lee WM. Acute liver failure. Lancet 2019;394(10201):869–81.
O'Grady JG, Alexander GJ, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97(2):439–45.
McPhail MJ, Farne H, Senvar N, et al. Ability of King's College criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure: A meta-analysis. Clin Gastroenterol Hepatol 2016;14(4):516–25.e5; quiz e43–5.
Koch DG, Tillman H, Durkalski V, et al. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol 2016;14(8):1199–206.e2.
Bernal W, Wang Y, Maggs J, et al. Development and validation of a dynamic outcome prediction model for paracetamol-induced acute liver failure: A cohort study. Lancet Gastroenterol Hepatol 2016;1(3):217–25.
Donnelly MC, Hayes PC, Simpson KJ. The changing face of liver transplantation for acute liver failure: Assessment of current status and implications for future practice. Liver Transpl 2016;22(4):527–35.
Reddy KR, Ellerbe C, Schilsky M, et al. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. Liver Transpl 2016;22(4):505–15.
Bernal W. Acute liver failure on the transplant waiting list: Acetaminophen both better and worse? Liver Transpl 2022;28(1):11–2.
Wong NZ, Reddy KR, Bittermann T. Acute liver failure etiology is an independent predictor of waitlist outcome but not posttransplantation survival in a national cohort. Liver Transpl 2022;28(1):39–50.
European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017;66(5):1047–81.
Ichai P, Legeai C, Francoz C, et al. Patients with acute liver failure listed for superurgent liver transplantation in France: Reevaluation of the Clichy-Villejuif criteria. Liver Transpl 2015;21(4):512–23.
Schiødt FV, Ostapowicz G, Murray N, et al. Alpha-fetoprotein and prognosis in acute liver failure. Liver Transpl 2006;12(12):1776–81.
Rutherford AE, Hynan LS, Borges CB, et al. Serum apoptosis markers in acute liver failure: A pilot study. Clin Gastroenterol Hepatol 2007;5(12):1477–83.
Schiødt FV, Bangert K, Shakil AO, et al. Predictive value of actin-free Gc-globulin in acute liver failure. Liver Transpl 2007;13(9):1324–9.
Woolbright BL, McGill MR, Staggs VS, et al. Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients. Toxicol Sci 2014;142(2):436–44.
Basta G, Del Turco S, Navarra T, et al.; Acute Liver Failure Study Group. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure. Liver Transpl 2015;21(6):847–54.
Srungaram P, Rule JA, Yuan HJ, et al. Plasma osteopontin in acute liver failure. Cytokine 2015;73(2):270–6.
Laursen TL, Sandahl TD, Stoy S, et al. Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure. Liver Int 2015;35(3):756–63.
Rosen HR, Biggins SW, Niki T, et al. Association between plasma level of galectin-9 and survival of patients with drug-induced acute liver failure. Clin Gastroenterol Hepatol 2016;14(4):606–12.e3.
Karvellas CJ, Speiser JL, Tremblay M, et al. Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure. Hepatology 2017;65(3):938–49.
Karvellas CJ, Speiser JL, Tremblay M, et al. Elevated serum liver-type fatty acid binding protein levels in non-acetaminophen acute liver failure patients with organ dysfunction. Dig Dis Sci 2021;66(1):273–83.
Spivak I, Arora J, Meinzer C, et al. Low serum hepcidin is associated with reduced short-term survival in adults with acute liver failure. Hepatology 2019;69(5):2136–49.
Slowik V, Borude P, Jaeschke H, et al. Leukocyte cell derived chemotaxin-2 (Lect2) as a predictor of survival in adult acute liver failure. Transl Gastroenterol Hepatol 2019;4:17.
Tavabie OD, Karvellas CJ, Salehi S, et al. A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure. J Hepatol 2021;75(2):424–34.
Patidar KR, Davis BC, Slaven JE, et al. Admission factor V predicts transplant-free survival in acute liver failure. Dig Dis Sci 2021;66(2):619–27.
Stravitz RT, Ellerbe C, Durkalski V, et al. Thrombocytopenia is associated with multi-organ system failure in patients with acute liver failure. Clin Gastroenterol Hepatol 2016;14(4):613–20.e4.
Glavind E, Gotthardt DN, Pfeiffenberger J, et al. The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. Orphanet J Rare Dis 2020;15(1):173.
Salehi S, Brereton HC, Arno MJ, et al. Human liver regeneration is characterized by the coordinated expression of distinct microRNA governing cell cycle fate. Am J Transplant 2013;13(5):1282–95.
Salehi S, Tavabie OD, Verma S, et al. Serum microRNA signatures in recovery from acute and chronic liver injury and selection for liver transplantation. Liver Transpl 2020;26(6):811–22.
Moller HJ, Gronbaek H, Schiodt FV, et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol 2007;47(5):671–6.
Strnad P, Zhou Q, Hanada S, et al. Keratin variants predispose to acute liver failure and adverse outcome: Race and ethnic associations. Gastroenterology 2010;139(3):828–35, 35.e1–3.
Court MH, Freytsis M, Wang X, et al. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther 2013;345(2):297–307.
Court MH, Peter I, Hazarika S, et al. Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab Dispos 2014;42(1):28–32.
Randesi M, Levran O, Correa da Rosa J, et al. Association of variants of arginine vasopressin and arginine vasopressin receptor 1A with severe acetaminophen liver injury. Cell Mol Gastroenterol Hepatol 2017;3(3):500–5.
Ajmera V, Huang H, Dao D, et al. Host genetic variant in CXCL16 may be associated with hepatitis B virus-related acute liver failure. Cell Mol Gastroenterol Hepatol 2019;7(2):477–9.e4.
Ugamura A, Chu PS, Nakamoto N, et al. Liver fibrosis markers improve prediction of outcome in non-acetaminophen-associated acute liver failure. Hepatol Commun 2018;2(11):1331–43.
Rutherford A, King LY, Hynan LS, et al. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology 2012;143(5):1237–43.